A novel strategy for treating acute liver failure:encapsulated proliferating human hepatocyte organoids  

作　　者：Xiangying Meng Aihui Liu Oulayvanh Phangthavong Yi Sun 

机构地区：[1]Institute of Reproductive and Stem Cell Engineering,School of Basic Medical Science,Central South University,Changsha,Hubei Province,China [2]Hunan Guangxiu Hospital,Hunan Normal University,Changsha,Hubei Province,China [3]National Engineering and Research Center of Human Stem Cells,Changsha,Hubei Province,China [4]Key Laboratory of Stem Cells and Reproductive Engineering,Ministry of Health,Changsha,Hubei Province,China

出　　处：《Biomaterials Translational》2024年第4期444-446,共3页生物材料转化电子杂志（英文）

摘　　要：Acute liver failure(ALF)is a short-term severe damage to hepatocytes caused by hepatotropic viruses,drug,etc.and accompanied by complications such as multi-organ failure and hepatic encephalopathy.1 The global incidence of ALF is estimated at over 1 million cases annually.2 Liver transplantation is currently the sole curative treatment for ALF,but due to the limitations of donor organ shortage,complications and long-term immunosuppression,hepatocytes transplantation has been proposed as an alternative strategy.3 However,the shortage of human primary liver cells(PHHs)and the difficulty in amplification in vitro hinder their clinical application.Stem cells can provide an abundant source of cells for the treatment of ALF,but the hepatocytes derived from them have limitations in expansion,insufficient liver function and safety problems.

关 键 词：ACUTE LIMITATIONS annually 

分 类 号：R575.3[医药卫生—消化系统] R318.1[医药卫生—内科学]